Clinical Insights: Impact of RASolute 302 on Clinical Practice in Previously Treated Metastatic PDAC
Key Points
-
The phase 3 RASolute 302 trial showed that daraxonrasib doubled median overall survival compared with investigator’s choice chemotherapy in previously treated metastatic pancreatic adenocarcinoma, increasing survival from 6.6 to 13.2 months among patients with RAS G12 mutations.
-
Because KRAS mutations are present in approximately 90% to 95% of pancreatic cancers, the benefits of daraxonrasib may be applicable to the vast majority of patients, representing one of the broadest precision oncology advances in the disease to date.
-
Daraxonrasib also improved progression-free survival, objective response rate, and patient-reported quality-of-life outcomes, highlighting clinically meaningful benefits beyond overall survival.
-
The safety profile was manageable with proactive supportive care, with rash, stomatitis, diarrhea, and gastrointestinal toxicities representing the most common adverse events; multiple ongoing trials are evaluating the agent in frontline and adjuvant settings.
At a Clinical Insights discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Brothers co-hosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, were joined by Andrew H. Ko, MD, of University of California, San Francisco; Eileen O’Reilly, MD, Memorial Sloan Kettering Cancer Center; Shubham Pant, MD, MBBS, MD Anderson Cancer Center; and Rachna Shroff, MD, MS, FASCO, University of Arizona. The panel discussed the phase 3 RASolute 302 trial evaluating daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Pancreatic adenocarcinoma remains one of the most challenging malignancies, with limited therapeutic advances over the past several decades. KRAS mutations are present in approximately 90% to 95% of pancreatic cancers, making RAS-directed therapy potentially relevant for the vast majority of patients with the disease. Alterations within the MAP kinase signaling pathway drive tumor growth, metastasis, and angiogenesis, making RAS an attractive therapeutic target that has long eluded successful drug development, Dr. O’Reilly said.
Daraxonrasib Delivers Landmark Survival Results in RASolute 302
Daraxonrasib is a novel RAS inhibitor designed to target RAS proteins in their active state. The agent functions through a unique mechanism involving cyclophilin A, effectively acting as a molecular glue that binds the active RAS protein and disrupts oncogenic signaling, ultimately leading to cancer cell death, Dr. Pant explained. Although the concept appears straightforward, he noted that the therapy represents the culmination of decades of research aimed at overcoming the challenges associated with directly targeting RAS.
Dr. Shroff reviewed the design of the global phase 3 RASolute 302 trial, which was led by Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and enrolled approximately 500 patients with mPDAC who had received 1 prior line of systemic therapy. Patients were randomly assigned to receive either daily oral daraxonrasib or investigator’s choice of chemotherapy, including gemcitabine, nab-paclitaxel, modified FOLFIRINOX (leucovorin [folinic acid], fluorouracil [5-FU], irinotecan, and oxaliplatin), NALIRIFOX (nanoliposomal irinotecan, 5-FU, oxaliplatin, and folinic acid), or FOLFOX (folinic acid, 5-FU, and oxaliplatin). The study’s dual primary end points were overall survival (OS) and progression-free survival (PFS) in patients with RAS G12 mutations, with additional analyses performed in the overall intention-to-treat population.
The results demonstrated a striking improvement in outcomes. Among patients with RAS G12 mutations, median OS reached 13.2 months with daraxonrasib compared with 6.6 months with chemotherapy. Similar findings were observed in the overall study population, where median OS was 13.2 months versus 6.7 months, respectively, corresponding to a hazard ratio of 0.40. Improvements were also seen in PFS and objective response rate, with 33.2% of patients with RAS G12 mutations responding to daraxonrasib compared with 11.8% in the chemotherapy arm. Patient-reported outcomes further supported the clinical benefit, showing delayed deterioration and improved quality of life (QoL) relative to standard chemotherapy.
The panel emphasized that the benefit was not limited to a narrowly defined molecular subgroup. Although most enrolled patients harbored KRAS G12 mutations, exploratory analyses suggested consistent activity across additional KRAS alterations and even among the small number of patients without detectable KRAS mutations. Future analyses will further evaluate allele-specific outcomes and the influence of co-occurring genomic alterations, but the available data suggest broad applicability across the pancreatic cancer population, Dr. O’Reilly said.
Managing Toxicities and Incorporating Daraxonrasib Into Practice
With daraxonrasib expected to enter clinical practice rapidly, much of the discussion focused on toxicity management and practical considerations for community oncologists. The most common adverse event (AEs) associated with treatment was rash, which Dr. Pant described as a predictable and generally manageable toxicity. Because the rash is often photosensitive, patients should receive counseling regarding strict sun protection measures, including routine sunscreen use. Prophylactic doxycycline and topical corticosteroids are frequently used to reduce severity, while dermatology consultation may be valuable for patients who develop more extensive reactions.
Additional toxicities included stomatitis, diarrhea, nausea, and other gastrointestinal AEs. Panelists stressed the importance of proactive supportive care, including early use of antidiarrheal medications, antiemetics, and oral hygiene measures. Gastrointestinal symptoms often occur early during treatment and can frequently be managed without interrupting therapy if patients are appropriately counseled and monitored, Dr. O’Reilly said.
Importantly, treatment discontinuation rates were relatively low despite these AEs. According to physicians involved in the study, many patients experienced meaningful improvements in cancer-related symptoms, appetite, and overall well-being while receiving therapy, making them highly motivated to remain on treatment. Dose interruptions and reductions were occasionally required for recurrent toxicities, but most patients were able to resume therapy successfully after symptom resolution.
The favorable efficacy and manageable toxicity profile make daraxonrasib an attractive option for a broad range of patients, including some who may not be ideal candidates for additional chemotherapy because of declining performance status, Dr. Ko explained. Although current data support use in the second-line setting, he suggested that the agent’s ease of administration and activity could ultimately expand its use across multiple treatment settings.
Expanding RAS-Directed Therapy Across the Pancreatic Cancer Continuum
The panel highlighted several ongoing studies designed to move daraxonrasib earlier in the disease course. The phase 3 RASolute 303 trial is evaluating the agent in the frontline setting both as monotherapy and in combination with gemcitabine plus nab-paclitaxel. Meanwhile, RASolute 304 is examining daraxonrasib in the adjuvant setting following completion of standard postoperative therapy, with the goal of reducing recurrence risk after surgical resection.
The panel agreed that RASolute 302 is an important advance in pancreatic cancer, demonstrating a doubling of median OS, significant improvements in PFS and QoL, and a manageable safety profile in a patient population with historically limited therapeutic options.
References
- Wolpin BM, Wainberg ZA, Hendifar A, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. J Clin Oncol. 2026;44(suppl 17):Abstr LBA5.
- O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMoa2605555